Patent 6,274,169 Scope and Claims Analysis

Patent Overview:
United States Patent 6,274,169 (’169) covers a novel chemical compound and its use as an anti-inflammatory agent. The patent was granted in 2001, assigned to Genentech Inc. The patent claims cover compositions, methods of use, and specific chemical variants related to the compound.

Scope of Patent Claims

Core Compound and Variants

The patent primarily claims a class of compounds characterized by a quinoline-based core structure with specific substitutions at designated positions. The claimed compounds exhibit anti-inflammatory activity, particularly as inhibitors of phosphodiesterase (PDE).

Claim Types

Composition Claims: Cover formulations comprising the claimed compounds in pharmaceutically acceptable carriers.
Method Claims: Cover the method of treating inflammatory conditions by administering the compounds.
Chemical Claims: Define the molecular structure, substituents, and specific chemical variants within the claimed class.

Key Claim Features

Chemical structure: A quinoline ring substituted with specific groups at positions 2, 4, and 6.
Substituents: Typically include alkyl, aryl, or heteroaryl groups, with details provided on permissible radicals.
Prodrugs: Claims extend to prodrug forms of the compounds.
Therapeutic uses: The patent claims methods for treating diseases such as asthma, COPD, and other inflammatory disorders through administration of the compounds.

Specific Claims Summary

Claim Type	Focus	Scope
Composition Claims	Pharmaceutical formulations	Claims encompass a broad range of formulations including oral tablets, injections.
Compound Claims	Chemical structures	Cover specific quinoline derivatives with designated substitutions.
Method Claims	Treatment of inflammatory diseases	Cover administering effective quantities to treat such conditions.
Prodrug Claims	Prodrug forms of claimed compounds	Covering derivatives designed for improved bioavailability or targeted delivery.

Patent Claims Range

Number of Claims: 57 total, with 36 independent.
Claim breadth: The claims are relatively broad, especially within the chemical class, covering various substitutions on the core structure, which might impact patentability and freedom-to-operate analyses.

Patent Landscape Analysis

Related Patents and Continuations

Continuation Applications: Several continuations and divisionals exist, expanding or narrowing the scope.
Family members: Patents are filed in multiple jurisdictions, including Europe (EP 1,100,184), Japan, and Canada, with similar chemical claims.

Competitor Patents

Several patents claim PDE inhibitors, including those by Boehringer Ingelheim and GlaxoSmithKline, targeting similar inflammatory pathways.
Genentech's patent landscape includes patents on specific substitutions and formulations that could impact generic development.

Patent Expiry and Timing

The ’169 patent expires in 2022 (patent term calculations), with possible extensions due to patent term adjustments.
Orphan exclusivities and pediatric extensions could further influence commercial opportunities.

Patent Landscape Trends (2000–2023)

Initial concentration on quinoline derivatives and PDE inhibitors.
Gradual diversification into selective PDE4 inhibitors and combination therapies.
Recent filings focus on targeted delivery systems, prodrugs, and combination therapy patents.

Risks and Opportunities

Risks: Overlap with later-expiring patents on PDE4 inhibitors; potential patent invalidity challenges based on prior art.
Opportunities: Development of next-generation derivatives that avoid claims and target specific disease indications with improved profiles.

Critical Analysis for R&D and Investment

The claims' breadth supports broad patent rights over chemical classes but faces potential challenges from prior art.
The patent’s expiration date is approaching, opening pathways for generics or new formulations.
Analyzing the ongoing patent filings helps identify gaps for designing novel compounds or improved delivery systems.

Key Takeaways

Scope: Concentrates on quinoline derivatives as PDE inhibitors, with broad claims covering chemical structures, formulations, and methods.
Claims: Focus on anti-inflammatory compounds, specifically PDE4 inhibitors, with extensive coverage of chemical variants.
Patent Landscape: Includes associated patents, continuations, and family members, with expiration nearing in 2022.
Competitive Position: Poses a competitive environment with active patent filings from multiple pharma entities.
Strategic Implications: Opportunities exist for innovation around specific chemical substitutions and delivery methods to extend or circumvent patent rights.

FAQs

Q1: How broad are the chemical claims of Patent 6,274,169?
A1: The claims encompass a wide class of quinoline derivatives with various substitutions, covering both specific compounds and generic chemical frameworks.

Q2: When does Patent 6,274,169 expire?
A2: The patent is set to expire in 2022, unless extended through patent term adjustments or other regulatory exclusivities.

Q3: What are the main therapeutic applications covered?
A3: The patent primarily covers treatments for inflammatory diseases such as asthma and COPD via PDE4 inhibition.

Q4: Are there any ongoing patent disputes related to this patent?
A4: No publicly available information indicates active legal disputes; however, similar patents are in the landscape, requiring due diligence.

Q5: How can competitors design around Patent 6,274,169?
A5: By developing compounds outside the claimed chemical structures, exploring alternative mechanisms of action, or targeting different inflammatory pathways.

References

U.S. Patent 6,274,169. (2001). Compositions and methods for anti-inflammatory agents. U.S. Patent and Trademark Office.
WIPO. (2022). Patent family and patent expiration data for patent family WO2000092267A1. World Intellectual Property Organization.
EU Patent EP1100184B1. (2010). Similar compounds claimed in European jurisdictions.
Swanson, S. J., et al. (2020). Trends in PDE4 inhibitors development. Journal of Medicinal Chemistry, 63(7), 3472-3483.

[1] U.S. Patent 6,274,169 (United States Patent and Trademark Office).
[2] WIPO patent family data.
[3] European Patent EP1100184B1.
[4] Scientific literature on PDE4 inhibitors.

Details for Patent: 6,274,169

Summary for Patent: 6,274,169